Healthy Aging Pharmacogenomics and Polypharmacy (HAPPY): Implementing PGx in primary care

Congenica® Suzanne Drury¹, Rand Dubis¹, Mikkel Christensen¹, Eunice Tan¹, Mahmoud Khodadi², Sara Humphrey², Judith Hayward² & Imran Rafi³ ¹Congenica Ltd, Cambridge, UK; ²Shipley Medical Practice, Affinity Care, Shipley, UK; ³The Longcroft Clinic, Banstead, UK

Background

- Polypharmacy is associated with increased adverse drug reactions (ADR; PMID: 24073682). In the UK 2million 65+yrs are on at least 7 medications a week.
- Adverse drug reactions have been shown to account for up to 16.5% hospital admissions (e.g. PMID: 357888071)
- Pharmacogenetic (PGx) testing is an effective strategy for optimising medication and potentially has considerable utility in the ageing population on polypharmacy. PGx-informed medication management in the over 65's has been shown to reduce medical changes(PMID: 35330421)
- Most prescribing takes place in primary care and ~20% new prescriptions for 56 drugs in primary care have an actionable drug-gene interaction (PMID:33464647)
- Several barriers have been identified preventing widespread adoption of PGx, including lack of evidence in using PGx results, uncertainty in interpretation of results, lack of integration with electronic medical records and decision support tools (PMID:27143951).

The Healthy Aging Pharmacogenomics and Polypharmacy project has two key aims:

- to develop an implementation plan for PGx in polypharmacy patients via a clinical study providing PGx reports to general practitioners
- to develop an innovative, scalable, integrated clinical decision support platform to support the implementation of PGx into primary care.

Here we describe the HAPPY clinical study

Methods



500 participants ≥50yrs ≥3 medications (≥1PGx)

Results



Saliva sample Patient registry:

- Medications • Healthcare interactions E.g.
- A&A admission • PFFS questionnaire
- ADR questionnaire (PMID:33094229 amendment)



Genotyping & report • Illumina GDA + Enhanced PGx Agena Veridose Core, CYP2D6 CNV & custom panels • Abomics




MDT



Online participant registry

30%



Medication changes

documented

actioned

28%

Enabling precision medicine




Healthcare interactions • 12mnth


• ADR


Questionnaire

• PFFS

• 3, 6, 12 months after PGx review










Reasons for participating


- To help the NHS, research, or other patients
- Interested in genetics and research
- Would like to reduce side effects or

Demographics of first 96 participants

Ethnicity



Other ethnic group	2
Mixed/multiple ethnic groups	1
Black/African/Caribbean/Black British	1
n/a	2




if they can reduce/stop medication


Number of **BNF** indication occurrences Cardiovascular 258 Gastrointestinal 64 37 Mental health 36 Pain management Other 160

Baseline BNF Indication

'Other' Baseline BNF Indication




Diabetes Respiratory Genitourinary Endocrine Other



Most common ADR per category

Category	Most common ADR
Cardiovascular	Shortness of breath
Respiratory	Breathing difficulties
Gastrointestinal	Constipation
Neurological	Memory problems

Baseline # ADRs per patient



Limitations

- Participants are majority white therefore not representative of the population
- ADRs are as reported by participant rather than healthcare professional therefore may be an adverse event rather than ADR
- \geq 3 medications selected as definition of polypharmacy rather than more common ≥5

Summary

- The HAPPY study will generate evidence to inform the implementation • and utility of PGx testing in primary care and develop the analytical solutions to support large scale implementation.
- Polypharmacy is also prevalent in other disciplines, e.g. oncology (PMID:33799547) and intellectual disability (PMID:35975635) therefore solutions which can be translated to other clinical settings would be beneficial.

Acknowledgements:

This project is part-funded by Innovate UK (project ID 10004421). The study has been approved by Research Association and Health and Care Research Wales (reference 21/NW/0166).

Congenica®



Healthy ageing challenge

Investment partnerships



